WALTHAM, Mass.—PerkinElmer Inc. added two new additions to its product offerings recently: the first two CE-marked chemiluminescence immunoassays for the detection of anti-Borrelia (Lyme disease) and anti-EBV/EBNA antibodies on its EUROIMMUN RA Analyzer 10 system. This system offers a compact automation solution for small- to medium-sized labs, and can complement high-throughput devices in larger labs.

 

“Lyme disease represents the most frequent tick-borne infection in the northern hemisphere, while EBV remains one of the most common human pathogens (herpesvirus 4) with a prevalence of up to 99 percent. Without treatment, Borrelia infections can lead to severe clinical symptoms. In case of EBV it is important to ensure early diagnosis due its high contagiousness,” said Dr. Wolfgang Schlumberger, CEO of EUROIMMUN, a PerkinElmer company. “By introducing assays for the RA Analyzer 10, we’ve extended our already comprehensive portfolio of serological assays for Lyme disease and EBV diagnostics.”